- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 03.07. | 4DMT lays off 25% of workforce while accelerating phase 3 eye gene therapy timeline | ||
| 02.07. | 53 biotech leaders urge FDA not to restrict mifepristone access over 'fatally flawed' report | ||
| 02.07. | Biotech VC raises $200M to focus on Japan's 'untapped source' of innovation | ||
| 02.07. | Vyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitor | ||
| 02.07. | Biokin, having landed BMS deal, posts ph. 3 cancer win for bispecific ADC | ||
| 02.07. | Why 'emboldened' activist investors are taking the fight to biotechs | ||
| 02.07. | Organon axes 'biggest potential opportunity' after flunking phase 2 trial | ||
| 01.07. | Catalio's $400M fund takes advantage of 'historic buyer's market in biotech' | ||
| 01.07. | Processa hands cancer candidate back to Opus Genetics after deciding milestone out of reach | ||
| 01.07. | Concentra acquires IGM Biosciences, continuing M&A streak with struggling biotechs | ||
| 01.07. | ROR deal: Oncternal sells cancer assets to mystery biotech for $3M, winds down operations | ||
| 01.07. | Beckley Psytech's psychedelic reduces depression symptoms in phase 2, triggering atai merger | ||
| 01.07. | Sanofi takes up option on Adagene biospecific and invests $25M, shielding partner from runway risk | ||
| 01.07. | BerGenBio, in wake of lead cancer drug's failure, opts to merge with radiopharma Oncoinvent | ||
| 01.07. | Fosun's Henlius pens $202M pact for regional rights to HanchorBio's phase 2 CD47 blocker | ||
| 30.06. | 'Emergency' at Apple Tree: VC sues key investor, warns portfolio biotechs are on brink of collapse | ||
| 30.06. | Amgen's FGFR2b-targeting cancer candidate boosts overall survival in phase 3 | ||
| 30.06. | Pfizer expands AI-powered small-molecule discovery collab with XtalPi | ||
| 30.06. | AbbVie reels in Capstan in $2.1B buyout, charting course for in vivo CAR-T market | ||
| 30.06. | INmune flunks phase 2 Alzheimer's trial, focuses on subgroup efficacy to fuel partnering plans | ||
| 30.06. | Moderna's mRNA flu vaccine beats approved competitor in latest phase 3 win, teeing up push to FDA | ||
| 30.06. | Pliant ends lung disease program after assessing rise in adverse events from bexotegrast trial | ||
| 27.06. | CytoDyn must face investor lawsuit alleging misleading claims in COVID, HIV drug debacle | ||
| 27.06. | Turnstone, once allied with AbbVie and Takeda, accepts $8M Xoma buyout | ||
| 27.06. | Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .